Go Deep
Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 17,648 | -60.3 | 1.34 | 0.73 | 3,849.51 |
Takeda Pharmaceutical Company Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 1,219,900,000,000.0 | 1,094,541,000,000.0 | 1,191,698,000,000.0 | 1,112,796,000,000.0 |
| Net Profit | 113,197,000,000.0 | -368,471,000,000.0 | 103,640,000,000.0 | -11,802,000,000.0 |
| EPS | 71.7 | — | — | — |
Takeda Pharmaceutical Company Limited Revenue & Profit: Last 4 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Revenue | 4,505,720,000,000.0 | 4,581,551,000,000.0 | 4,263,762,000,000.0 | 4,027,478,000,000.0 |
| Net Profit | -152,390,000,000.0 | 107,928,000,000.0 | 144,067,000,000.0 | 317,017,000,000.0 |
| EPS | 121.8 | 68.4 | 92.1 | 204.3 |
Takeda Pharmaceutical Company Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 15,511,506,000,000.0 | 14,248,344,000,000.0 | 15,108,792,000,000.0 | 13,957,750,000,000.0 | — |
| Total Liabilities | 8,080,857,000,000.0 | 7,312,365,000,000.0 | 7,834,787,000,000.0 | 7,603,079,000,000.0 | — |
| Total Equity | 7,429,441,000,000.0 | 6,935,084,000,000.0 | 7,273,264,000,000.0 | 6,354,122,000,000.0 | — |
Takeda Pharmaceutical Company Limited Assets & Liabilities Breakdown (JPY millions)
What it owns — Mar 2026
Cash & short-term investments 4.1%Receivables 5.6%Inventory 9.0%Fixed assets (tangible) 13.7%Intangible assets 59.5%Long-term investments 2.9%Other assets 5.2%
How it's funded — Mar 2026
Short-term debt 3.3%Long-term debt 28.2%Payables 2.1%Other liabilities 18.5%Shareholders' equity 47.9%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 636,942.0 | 405,589.0 | 472,889.0 | 553,704.0 |
| Receivables | 876,348.0 | 725,254.0 | 697,610.0 | 681,694.0 |
| Inventory | 1,396,620.0 | 1,217,349.0 | 1,209,869.0 | 986,457.0 |
| Fixed assets (tangible) | 2,120,639.0 | 1,968,209.0 | 1,989,777.0 | 1,691,229.0 |
| Intangible assets | 9,228,358.0 | 8,955,990.0 | 9,684,750.0 | 9,060,380.0 |
| Long-term investments | 448,737.0 | 361,926.0 | 430,608.0 | 378,857.0 |
| Other assets | 803,862.0 | 614,027.0 | 623,289.0 | 605,429.0 |
| Liabilities & equity | ||||
| Short-term debt | 512,157.0 | 548,939.0 | 367,251.0 | 339,600.0 |
| Long-term debt | 4,369,681.0 | 3,966,326.0 | 4,476,501.0 | 4,042,741.0 |
| Payables | 324,368.0 | 308,450.0 | 319,955.0 | 307,453.0 |
| Other liabilities | 2,874,651.0 | 2,488,650.0 | 2,671,080.0 | 2,913,285.0 |
| Shareholders' equity | 7,430,649.0 | 6,935,979.0 | 7,274,005.0 | 6,354,671.0 |
| Net tangible assets | -1,798,917.0 | -2,020,906.0 | -2,411,486.0 | -2,706,258.0 |
Takeda Pharmaceutical Company Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 1,041,431,000,000.0 | 1,057,182,000,000.0 | 716,344,000,000.0 | 977,156,000,000.0 | — |
| Investing Activities | -369,141,000,000.0 | -367,060,000,000.0 | -463,862,000,000.0 | -607,102,000,000.0 | — |
| Financing Activities | -496,820,000,000.0 | -751,425,000,000.0 | -354,416,000,000.0 | -709,148,000,000.0 | — |